Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiotricityBTCY EV-to-FCF is 200.10 as of Sep. 10, 2026. The stock has 6 warning signs investors should review. Among 409 Medical Devices & Instruments companies, Biotricity ranks worse than 94.62% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Biotricity's Enterprise Value is $32.42 Mil.
Biotricity's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 was $0.16 Mil. Therefore, Biotricity's EV-to-FCF for today is 200.10.
The historical rank and industry rank for Biotricity's EV-to-FCF or its related term are showing as below:
BTCY'
s EV-to-FCF Range Over the Past 10 Years
Min: -100.74 Med: -5.81 Max: 208.88
Current: 200.1
During the past 13 years, the highest EV-to-FCF of Biotricity was 208.88. The lowest was -100.74. And the median was -5.81.
BTCY's EV-to-FCF is ranked worse than 94.62% of 409
companies
in the Medical Devices & Instruments industry
Industry Median: 23.68
vs BTCY: 200.10
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biotricity's share price for today is $0.09.
Biotricity's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.133.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Biotricity EV-to-FCF Related Terms
Biotricity EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Biotricity's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biotricity's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotricity EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Biotricity's EV-to-FCF falls into.
Biotricity's current Enterprise Value is $32.42 Mil.
Biotricity's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.16 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotricity (BTCY) has a EV-to-FCF of 200.10 as of Sep. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biotricity and its competitors. According to the industry distribution chart, Biotricity ranks #387 out of 409 companies in the Medical Devices & Instruments industry, placing it in the top 94.6%.
Is Biotricity's EV-to-FCF too high?
Biotricity's current EV-to-FCF is 200.10. The Medical Devices & Instruments industry median EV-to-FCF is 23.68. Biotricity's value of 200.10 is 745% above this industry median. Based on the distribution chart, Biotricity ranks #387 out of 409 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Biotricity's EV-to-FCF compare to IVF and CSDX?
According to the Medical Devices & Instruments industry distribution chart, Biotricity ranks #387 out of 409 companies for EV-to-FCF. This places Biotricity in the lower half of its industry. The industry median EV-to-FCF is 23.68. Biotricity's value of 200.10 is 745% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.68, based on 409 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotricity's current EV-to-FCF of 200.10 is 745% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Biotricity and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotricity's current EV-to-FCF is 200.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotricity stock overvalued right now?
Based on GuruFocus' analysis, Biotricity (BTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $0.37, compared to a current price of $0.09 — trading 75.7% below its estimated fair value. The current EV-to-FCF is 200.10 and 745% above the Medical Devices & Instruments industry median of 23.68. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Biotricity (BTCY), the current EV-to-FCF is 200.10 as of Sep. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed; Bioheart, which is a personal heart monitor; Biokit, and Biocare health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTCY has been successfully added to your 
